Amano Enzyme establishes new European hub at Milton Park

The world’s leading manufacturer of speciality enzymes, has established its new Europe, Middle East and Africa (EMEA) hub at Milton Park.

Amano Enzymes, the Japanese biotechnology company – which uses its enzymes to boost the flavour, texture, colour, digestion and nutritional profiles of products in the booming plant-based ‘alternatives’ market – has occupied 5,682 sq ft of office and laboratory space to drive further company growth.

The move to Milton Park coincides with the company’s 30th anniversary in the UK, while 2023 marks its 40th anniversary in Europe, with plans underway for a significant recruitment drive across R&D, sales and customer service roles, which will see the company nearly double its workforce at the Park in the coming years.

Amano’s new premises at Milton Park, which oversees all operations across its EMEA sites, is undergoing a state-of-the-art fit-out. Once complete, the bespoke laboratory, comprising cutting-edge R&D equipment, will enable the company to further expand into strategic focus areas, such as plant-based food and drinks. In November, Amano will be showcasing its latest innovations featuring non-dairy drink options.

Milton Park offers the space to create bespoke laboratories in close proximity to Reading University’s Food and Nutritional Sciences hub, making it the ideal location for Amano Enzyme’s new EMEA base. Additionally, we were keen to find an innovative work environment with excellent public transport links. We’re thoroughly looking forward to growing our pipeline of work with the support of these new premises while at the same time networking with the many other pioneering biotechnology companies based at Milton Park.

Kazumi Washisaka, Managing Director at Amano Enzyme

To find out more about Amano Enzyme and its vacancies,  visit: www.amano-enzyme.com

Recent news

Sauber Motorsport opens Technology Centre at Bicester Motion

Sauber Motorsport opens Technology Centre at Bicester Motion

Sauber Motorsport has opened its new Technology Centre at Bicester Motion. The primary purpose of the facility at the 444-acre future mobility estate is to enhance and expand the team’s technical capabilities, to ensure the team is well-positioned to attract top...

read more
Immunocore Wins Prix Galien UK Award for KIMMTRAK

Immunocore Wins Prix Galien UK Award for KIMMTRAK

Immunocore has been awarded a Prix Galien UK award for KIMMTRAK, its treatment for metastatic uveal melanoma- a rare and aggressive form of eye cancer. The Prix Galien UK is one of the highest accolades in the life sciences sector, recognising outstanding innovation...

read more
Loading...